Ionis Pharmaceuticals(IONS)

Focus: Ionis Pharmaceuticals is a pure-play RNA-targeted drug company founded in 1989, specializing in antisense oligonucleotide (ASO) and gene therapy modalities for neurology and rare genetic diseases. The company is public (NASDAQ: IONS) with a ~35-year track record in RNA-based therapeutics.

Neurology Gene Therapy

Profile data last refreshed 16h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Ionis Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Ionis Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Generated by Claude from Ionis Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$227M

Key Products

TRYNGOLZA

Hypertriglyceridemia

Growth7.6yr

Lead marketed product in lipid-lowering space; faces direct competition from Arrowhead's RNAi candidate.

DAWNZERA

Help build intelligence for Ionis Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Evaluation of Outcome Metrics in Alexander Disease

Alexander Disease

N/A

Clinical Trials (1)

NCT02714764Evaluation of Outcome Metrics in Alexander Disease

N/A

Donidalorsen

Hereditary Angioedema

N/A

Clinical Trials (1)

NCT06415448Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

N/A

Scintigraphy scan

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

N/A

Clinical Trials (1)

NCT06073587The CARDIO-TTRansform Scintigraphy Sub-study

N/A

Inotersen

Amyloidosis, Hereditary

N/A

Clinical Trials (1)

NCT03400098ATTR Expanded Access Program (EAP) by Ionis

N/A

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

neurofilament light chain

Hereditary Amyloidosis, Transthyretin-Related

N/A

Clinical Trials (1)

NCT05311488Early Detection of Neuropathy in ATTRv

N/A

99m-technetium pyrophosphate scintigraphy

Amyloidosis

N/A

Clinical Trials (1)

NCT05259072carDIo-ttranSSfOrm nucLEar Imaging Study

N/A

Natural History and Functional Status Study of Patients With Lafora Disease

Lafora Disease

N/A

Clinical Trials (1)

NCT03876522Natural History and Functional Status Study of Patients With Lafora Disease

N/A

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Peliza

Pelizaeus-Merzbacher Disease

N/A

Clinical Trials (1)

NCT05659901Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

N/A

Olezarsen

Familial Chylomicronemia Syndrome

N/A

Clinical Trials (2)

NCT07727538A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

Phase 3

NCT06360237Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl C

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

N/A

Clinical Trials (1)

NCT06014541Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

N/A

Lumbar puncture

Spinocerebellar Ataxia Type 2

N/A

Fomivirsen sodium

Cytomegalovirus Retinitis

N/A

Clinical Trials (1)

NCT00002355A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes

N/A

Fomivirsen sodium

Cytomegalovirus Retinitis

N/A

Clinical Trials (1)

NCT00002187A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

N/A

Cardiac MRI

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

N/A

Clinical Trials (1)

NCT06073574CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

N/A

Angelman Syndrome Video Assessment (ASVA) Source Material Study

Angelman Syndrome

N/A

Clinical Trials (1)

NCT05637697Angelman Syndrome Video Assessment (ASVA) Source Material Study

N/A

ION251

Relapsed Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT04398485A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

IONIS-ENaCRx

Healthy Subjects

PHASE_1

Clinical Trials (1)

NCT03647228A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis

Phase 1

ISIS 388626

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT00836225Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Phase 1

IONIS TMPRSS6-Lrx

Thalassemia

PHASE_1

Clinical Trials (1)

NCT03165864Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers

Phase 1

Olezarsen

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT05579860A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Phase 1

IONIS ANGPTL3-LRx

Hypertriglyceridemia

PHASE_1

Clinical Trials (1)

NCT02709850Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Phase 1

Eplontersen

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT04302064A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants

Phase 1

mipomersen

Healthy Volunteer

PHASE_1

Clinical Trials (1)

NCT01061814A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Phase 1

ISIS 353512

Inflammatory Diseases

PHASE_1

Clinical Trials (1)

NCT00734240Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers

Phase 1

ION356

Pelizaeus-Merzbacher Disease

PHASE_1

Clinical Trials (1)

NCT06150716Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)

Phase 1

ISIS 325568

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT00519727Safety Study of ISIS 325568 in Healthy Volunteers

Phase 1

ION904

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04731623A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904

Phase 1

mipomersen sodium

Healthy

PHASE_1

Clinical Trials (1)

NCT01090661A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Phase 1

APOC-III-L-Rx

Elevated Triglycerides (TG)

PHASE_1

Clinical Trials (1)

NCT02900027Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Phase 1

IONIS FXI-LRx

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT03582462A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers

Phase 1

ION269

Alzheimer Disease

PHASE_1

Clinical Trials (1)

NCT06673069Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

Phase 1

ISIS 333611

Familial Amyotrophic Lateral Sclerosis

PHASE_1

Clinical Trials (1)

NCT01041222Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Phase 1

ISIS 113715

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT00365781Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

Phase 1

Ionis AGT-LRx

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT03101878Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers

Phase 1

warfarin sodium

Healthy

PHASE_1

Clinical Trials (1)

NCT01133366A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Phase 1

ION547

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04934891A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547

Phase 1

Volanesorsen

Abnormalities, Cardiovascular

PHASE_1

Clinical Trials (1)

NCT02910635A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Phase 1

ION464

Multiple System Atrophy

PHASE_1

Clinical Trials (1)

NCT04165486Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

Phase 1

IONIS-APO

Elevated Lipoprotein(a)

PHASE_1

Clinical Trials (1)

NCT02414594Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Phase 1

ISIS 681257

Renal Impairment

PHASE_1

Clinical Trials (1)

NCT03506854Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Phase 1

mipomersen

Healthy Volunteer

PHASE_1

Clinical Trials (1)

NCT01414881Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

Phase 1

IONIS MAPTRx

Mild Alzheimer's Disease

PHASE_1

Clinical Trials (1)

NCT03186989Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Phase 1

Placebo

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT05337878A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

Phase 1

Placebo

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT03263507Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

Phase 1

ION537

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT04659096A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors

Phase 1

AZD9150

Advanced Adult Hepatocellular Carcinoma

PHASE_1

Clinical Trials (1)

NCT01839604A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma